Secukinumab Vs. Adalimumab for Treatment of Ankylosing Spondylitis- A Cost Per Responder Analysis at 52 Weeks from an Argentinian Perspective

Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.771
https://www.valueinhealthjournal.com/article/S1098-3015(17)31105-1/fulltext
Section Title : Disease-Specific Studies
Section Order : 736
First Page : A535
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31105-1&doi=10.1016/j.jval.2017.08.771
HEOR Topics :
Tags :
Regions :